Neisseria meningitidis group Y capsular polysaccharide-specific B-cell receptors and tetanus toxoid-specific CD4+ T-cell receptors (MenY BCR and TT-specific TCR)

This target complex involves the coordinated engagement of B-cell receptors (BCRs) and CD4+ T-cell receptors (TCRs) to elicit a robust immune response against Neisseria meningitidis serogroup Y. The BCR specifically recognizes the capsular polysaccharide of the bacteria, which is a T-cell independent antigen. By conjugating this polysaccharide to a tetanus toxoid carrier protein, the vaccine enables the recruitment of tetanus toxoid-specific CD4+ T-cells (Knuf et al., 2011, Vaccine). These T-cells recognize processed peptides from the carrier protein presented by B-cells, providing the essential help required for B-cell affinity maturation and the generation of long-lived memory B-cells. This mechanism is the foundation of modern conjugate vaccines, ensuring high-titer, high-affinity antibody production and long-term protection against invasive meningococcal disease (WHO, 2011). The interaction converts a typically weak, transient immune response into a potent, durable one suitable for all age groups.

Other names

MenY-specific BCRTT-specific TCRMeningococcal serogroup Y polysaccharide B-cell receptorTetanus toxoid-specific T-cell receptorMenY-TT conjugate vaccine target complex

The conjugate vaccine binds to the B-cell receptor (BCR) specific for the MenY polysaccharide; the B-cell internalizes the conjugate and presents carrier-derived peptides (tetanus toxoid) via MHC class II to CD4+ T-cells, which then provide the necessary signals for B-cell differentiation into plasma cells and memory cells (Pollard et al., 2009, Nature Reviews Immunology).